Publications

NOTE: The US Food and Drug Administration (FDA) approved the premarket approval application (PMA) for SIR-Spheres microspheres in March 2002 for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUdR (Floxuridine).

NOTE: The information below covers a use that has not been approved by the FDA.

1. Lim, L., Gibbs, P., Yip, D., et al. (2005). "Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies." Internal Medicine Journal 35: 222 - 227.


2. Murthy, R., Xiong, H., Nunez, R., et al. (2005). "Yttrium 90 Resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: Preliminary results." Journal of Vascular and Interventional Radiology 16: 937 - 945.


NOTE: The information below covers a use that has not been approved by the FDA.

top

3. Wong, C. O., Qing, F., Savin, M., et al. "Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F] fluorodeoxyglucose positron emission tomographic imaging". J Vasc Interv Radiol 2005; 16:1101-1106.

NOTE: The information below covers a use that has not been approved by the FDA.

4. Popperl, G., Helmberger, T., et al. "Selective internal radiation therapy with SIR-Spheres microspheres in patients with nonresectable liver tumors". Cancer Biotherapy & Radiopharmaceuticals 20(2): 200-208. 2005


NOTE: The information below covers a use that has not been approved by the FDA.

5. Liu, D., Salem, R., Bui, J., et al. "Angiographic considerations in patients undergoing liver- directed therapy". J Vasc Interv Radiol 2005; 16:911-935


NOTE: The information below covers a use that has not been approved by the FDA.

top

6. Murthy, R., Nunez, R., et al. "Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications". RadioGraphics 2005; 25:S41-S55.


7. Van Hazel, G., Blackwell, A., Anderson, J., et al. (2004). "Randomised phase 2 trial of SIR-Spheres microspheres plus Fluorouracil/Leucovorin chemotherapy versus Fluorouracil/Leucovorin chemotherapy alone in advanced colorectal cancer." Journal of Surgical Oncology 88: 78 - 85.


8. Stubbs, R. and Wickremesekera, S. (2004). "Selective internal radiation therapy (SIRT): a new modality for treating patients with colorectal liver metastases." HPB 6(3): 133 - 139.

top

9. Yip, D., Allen, R., Ashton, C., et al. (2004). "Letter: Radiation-induced ulceration of the stomach secondary to hepatic embolization with radioactive yttrium microspheres in the treatment of metastatic colon cancer." Journal of Gastroenterology and Hepatology 19(3): 347 - 349.


10. Kennedy, A., Nutting, C., Coldwell, D., et al. (2004). "Pathologic response and microdosimetry of Y⁹⁰ microspheres in man: review of four explanted whole livers." International Journal of Radiation Oncology, Biology and Physics 60(5): 1552-1563.


11. Liu, L., Zhang, W. and Jiang, H. (2003). "Current treatment for liver metastases from colorectal cancer." World Journal of Gastroenterology 9(2): 193 - 200.

top

12. Gray, B., Van Hazel, G., Hope, M., et al. (2001). "Randomised trial of SIR-Spheres microspheres plus chemotherapy vs chemotherapy alone for treating patients with liver metastases from primary large bowel cancer." Annals of Oncology 12: 1711 - 1720.


13. Stubbs, R., Cannan, R. and Mitchell, A. (2001). "Selective Internal Radiation Therapy with yttrium-90 microspheres for extensive liver metastases." Journal of Gastrointestinal Surgery 5: 294 - 302.


14. Moroz, P., Anderson, J., Van Hazel, G., et al. (2001). "Effect of Selective Internal Radiation Therapy and Hepatic Arterial Chemotherapy on Normal Liver Volume and Spleen Volume." Journal of Surgical Oncology 78: 248 - 252.


15. Gray, B., Van Hazel, G., Buck, M., et al. (2000). "Treatment of colorectal liver metastases with SIR-Spheres microspheres plus chemotherapy." GI Cancer 3: 249 - 257.

top